A phase 2 randomized, open label, multi-center study of the use of prandial inhaled technosphere insulin [insulin] in combination with basal subcutaneous lantus as basal insulin [insulin glargine] versus prandial subcutaneous novorapid [insulin aspart] in combination with basal subcutaneous lantus insulin in subjects with type 1 diabetes mellitus.
Phase of Trial: Phase II
Latest Information Update: 07 Oct 2009
At a glance
- Drugs Insulin; Insulin aspart; Insulin glargine
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 16 Oct 2007 New trial record.